Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0799
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2638
    +0.0016 (+0.12%)
     
  • USD/JPY

    151.2110
    -0.1610 (-0.11%)
     
  • Bitcoin USD

    70,436.24
    -652.13 (-0.92%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

AcelRx Pharmaceuticals (ACRX): Strong Industry, Solid Earnings Estimate Revisions

One stock that might be an intriguing choice for investors right now is AcelRx Pharmaceuticals, Inc. ACRX. This is because this security in the Medical-Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical-Drugs space as it currently has a Zacks Industry Rank of 71 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, AcelRx Pharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

In fact, over the last 60 days, current quarter estimates have narrowed from a loss of 24 cents per share to a loss of 22 cents per share, while current year estimates have narrowed from a loss of 92 cents per share to a loss of 88 cents per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal.

So, if you are looking for a decent pick in a strong industry, consider AcelRx Pharmaceuticals. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ACELRX PHARMACT (ACRX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement